12 Years on Russian Pharma Market

News

К списку новостей

12 Years on Russian Pharma Market

Throughout our history we are helping to preserve lives and health of people expediting implementation and increasing accessibility of modern treatments and diagnostics in Russia.
Lancet promotes strategic partnership with leading Russian and foreign pharmaceutical manufacturers and follows global trends in medicine to file a balanced portfolio that meets the demands of up-to-date medical practice. We are striving to set our portfolio with the latest products to expedite the launch of highly effective medical products increasing the quality of medical care and saving people’s lives.
Lancet confirms its status of a socially responsible Company and continues to successfully develop the key therapeutic areas and search for new prospective market segments. We have established expertise in many therapeutic areas, such as anesthesiology and reanimation, pulmonology, oncology, renal replacement therapy, anti-thrombotic therapy, imaging tools. We’re opening new areas of rheumatology, metabolism and digestion and looking into the prospects for entering the area of neurology in 2020.
The experience we have gained together with our corporate resources and market prospects enable us to reinforce our competitive position and set more ambitious goals.
We appreciate our collaboration and confidence of Partners and Clients, and we are happy to face the next stage of Lancet’s development together.